Reply to: "Bioinformatics and Immunohistochemistry Show Preserved Expression of GDNF Receptor RET in Parkinson's"

Alan Whone^{1

2}

Affiliations

¹ School of Translational Health Sciences, University of Bristol, Bristol, United Kingdom.
² Department of Neurology, Southmead Hospital, Bristol, United Kingdom.

Comment

Alan Whone. Mov Disord. 2023 Jun.

. 2023 Jun;38(6):1117-1118.

doi: 10.1002/mds.29438.

Alan Whone^{1

2}

¹ School of Translational Health Sciences, University of Bristol, Bristol, United Kingdom.
² Department of Neurology, Southmead Hospital, Bristol, United Kingdom.

No abstract available

Comment on

Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's.
Giles Doran C, Wilson F, Goulding SR, Mazzocchi M, Collins LM, Sullivan AM, O'Keeffe GW. Giles Doran C, et al. Mov Disord. 2023 Jun;38(6):1115-1116. doi: 10.1002/mds.29443. Mov Disord. 2023. PMID: 37475614 No abstract available.

1. Giles Doran C, Wilson F, Goulding SR, Mazzocchi M, Collins LM, Sullivan AM, O'Keeffe GW. Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's. Mov Disord 2003;38(6):1115-1116.
1. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60(1):69-73.
1. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59(3):459-466.
1. Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S, et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. Brain 2019;142(3):512-525.
1. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010;9(12):1164-1172.